Kamada (XTAE:KMDA) Debt-to-Revenue : 0.06 (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Kamada Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Kamada's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₪5.4 Mil. Kamada's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₪27.0 Mil. Kamada's annualized Revenue for the quarter that ended in Mar. 2024 was ₪559.2 Mil. Kamada's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.06.

Kamada Debt-to-Revenue Historical Data

The historical data trend for Kamada's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kamada Debt-to-Revenue Chart

Kamada Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

0.05

0.04

0.24

0.16

0.06

Kamada Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial															0.19	0.14	0.04	0.06	0.06

Competitive Comparison of Kamada's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Kamada's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kamada's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kamada's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Kamada's Debt-to-Revenue falls into.

Kamada Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Kamada's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(5.127	+	27.555)	/	527.97
	=	0.06

Kamada's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(5.435	+	26.962)	/	559.18
	=	0.06

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

Kamada Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Kamada's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Kamada (XTAE:KMDA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (XTAE:KMDA) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

KMDA:USA

Address

2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402

Website

https://www.kamada.com

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.